Department of Biostatistical Science

1998 Publications

Advanced Ovarian Cancer Trialists' Group: Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Coombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Kaye SB, Laing AH, Landoni F, Leonard RC, Lewis C, Liu PY, Mangioni C, Marsoni S, Meerpohl H, Omura GA, Parmar MKB, Pater J, Pecorelli S, Presti M, Sauerbrei W, Skarlos DV, Smaley RV, Solomon HJ, Stewart LA, Sturgeon JFG, Tattersall MHN, Wharton JT, ten Bokkel Huinink WW, Tomirotti M, Torri W, Trope C, Turbow M, Vermorken JB, Web MJ, Wilbur DW, Williams CJ, Wiltshaw E, Yeap BY. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998; 78(11):1479-1487.

Androkites AL, Werger AM, Young ML. Comparison of axillary and infrared tympanic membrane thermometry in a pediatric oncology outpatient setting. J Pediatr Oncol Nurs 1998; 15(4):216-222.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation. Blood. 1998; 91(10):3671-3680.

Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei III E, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998; 16(3):1000-1007.

Berlin JD, Propert KJ, Trump D, Wilding G,, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer. Am J Clin Oncol. 1998; 21(2):171-176.

Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thürlimann B, Forbes JF, Goldhirsch A, Senn H-J, Rudenstam C-M for the International Breast Cancer Study Group (IBCSG). Br J Cancer. 1998; 78(5):686-693.

Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, Gelber RD, Castiglione-Gertsch M, Hürny C. Quality of life assessment in International Breast Cancer Study Group (IBCSG) Trials: practical issues and factors associated with missing data. Statistics in Medicine. 1998; 17: 587-601.

Billett AL, Gelber RD, Tarbell NJ, Dalton V, Donnelly M, Sallan SE. Results of Dana Farber Cancer Institute-Consortium Childhood Acute Lymphoblastic Leukemia Protocols. International Journal of Pediatric Hematology/Oncology. 1998; 5(2-4):115-123.

Bosch RJ, Ryan LM. Generalized Poisson models arising from Markov processes. Statistics and Probability Letters. 1998; 39:205-212.

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339(23):1649-1656.

Castiglione-Gertsch M, Tattersall M, Hacking A, GoldhirschA, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn HJ, Rudenstam CM, for the International Breast Cancer Study Group. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. Eur J Cancer . 1998; 33(14):2321-2325.

Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bornstein B, Connolly J, Schnitt S, Silver B., Manola J, Harris J, Garber J. Family history and treatment outcomes in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1998; 16(6): 2045-2051.

Chang AY, Kim KM, Boucher H, Bonomi P, Stewart JA, Darp DD, Blum RH. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma. Cancer. 1998; 82:292-300.

Chang AY, Putt M, Pandya KJ, Harris J, Gelman R, Tormey DC, Falkson G. Induction chemotherapy of dibromodulcitol, adriamycin, vincristine, tamoxifen, and halotestin with methotrexate in metastatic breast cancer. An Eastern Cooperative Oncology Group Study (E1181). Am J Clin Oncol. 1998; 21(1):99-104.

Coates AS, Gelber RD, Goldhirsch A for the International Breast Cancer Study Group. Subsets within the chemotherapy overview. Lancet 1998; 352:1783.

Cole BF, Gelber RD, Goldhirsch A. In reply to: Messori A, Trippoli S: Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients (letter)? J Clin Oncol. 1998; 16(11):3718.

Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998; 16(7):2339-2344.

Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16(4): 1331-1339.

D'Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imagining: a new predictor of tumor response to neoadjuvant androgen suppression therapy. J Urol 1998; 51(2):287-292.

Davidov O, Zelen M. Urn sampling and the proportional hazard model. Lifetime Data Analysis 1998; 4:309-327.

DeHaan G, Gelman R, Watson A, Yunis E, Van Zant G. A putative gene causing variability in lifespan among genotypically identical mice. Nat Genetics 1998; 19(2):114-6.

Diller L, Ghahremani M, Morgan J, Grundy P, Reeves C, Breslow N, Green D, Neuberg D, Pelletier J, Li FP. Constitutional WT1 Mutations in Wilms Tumor Patients. J Clin Oncol 1998: 16(11): 3634-3640.

Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E III. Dose escalation of the hypoxic cell sensitizier etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clinical Cancer Research 1998; 4:1443-1449.

Eng C, Thomas GA, Neuberg DS, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Williams ED, Ponder AJ. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1998; 83(12):4310-3.

Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 1998; 17:667-677.

Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med 1998; 17:781-796.

Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon -2b versus dacarbazine with tamoxifen versus dacarbazine with interferon -2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998; 16(5): 1743-1751.

Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998; 16:1669-1676.

Fetting JH, Gray R, Fairclough DL, Smith TJ, Marolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abelof MD. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an intergroup study. J Clin Oncol. 1998; 16 (7): 2382-2391.

Forastiere AA, Shank D, Neuberg D, Taylor IV, SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. An Eastern Cooperative Oncology Group Trial (PA390). Cancer. 1998; 82:2270-2274.

Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson, KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM. High-dose chemoradiotherapy and anti-b-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998; 16(1):13-88.

Gaylor D, Ryan L, Krewski D, Zhu Y. Procedures for calculating benchmark doses for health risk assessment. Regulatory Toxicology and Pharmacology. 1998; 28:150-164.

Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A for the International Breast Cancer Study Group. Quality of life assessment in the adjuvant setting: is it relevant? In: Senn, H.-J., Gelber, R.D., Goldhirsch, A., Thürlimann, B., eds. Adjuvant Therapy of Primary Breast Cancer VI. Berlin, Germany: Springer-Verlag, 1998:373-389.

Glasziou PP, Cole BF, Gelber RD, Hilden J, Simes RJ. Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine. 1998; 17:1215-1229.

Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998; 16(1):19-26.

Goldhirsch A, Coates AS, Castiglione-Gertsch M, Gelber RD. New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction (commentary). Ann Oncol 1998; 9:973-976.

Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD, for the International Breast Cancer Study Group. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol 1998; 9:489-493.

Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD, for the International Breast Cancer Study Group. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998; 16(4):1358-1362.

Goldhirsch A, Glick JH, Gelber RD, Senn H-J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. JNCI 1998; 90(21):1601-1608.

Goldhirsch A, Glick JH, Gelber RD, Senn H-J. International consensus panel on the treatment of primary breast cancer V: update 1998. In: Senn, H.-J., Gelber, R.D., Goldhirsch, A., Thürlimann, B., eds. Adjuvant Therapy of Primary Breast Cancer VI. Berlin, Germany: Springer-Verlag, 1998:481-497.

Gollob JA, Schnipper CP, Orsini E, Murphy E, Daley JF, Lazo SB, Frank DA, Neuberg D, Ritz J. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998; 102(3):561-75.

Gray RJ. On tests for group variation with a small to moderate number of groups. Lifetime Data Analysis 1998; 4:139-148.

Gray RJ. On regression analysis with incomplete covariate data. Commun Statist Theory Meth 1998; 27(11):2641-2662.

Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology -- an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group. Blood 1998; 91(7):2501-2507.

Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in ECOG Clinical Trials: Problems and Solutions. Stat Med 1998; 17:547-559.

Harrington DP. Linear Rank Tests in Survival Analysis. In: Armitage P, Colton T,eds. Encyclopedia of Biostatistics. Vol. 3, England, UK:John Wiley & Sons Ltd, 1998:2263-73.

Harrington DP. Partial Likelihood. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Vol. 4, England, UK: John Wiley & Sons Ltd, 1998:3266-68.

Hellman R, Neuberg DS, Wagner H, Grunnet M, Robins HI, Karp D, Flynn P, Adams G. A therapeutic trial of radiation therapy with Vincristine, VP-16, and Procarbizine (VVP) in high grade intracranial gliomas: an Eastern Cooperative Oncology Group Study (E2392). J Neuroncology. 1998; 37:55-62.

Hoeting JA, Ibrahim JG. Bayesian predictive simultaneous variable and transformation selection in the linear model. Computational Statistics and Data Analysis 1998; 28:87-103.

Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson III AB. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an ECOG study. J Clin Oncol 1998; 16(1): 317-323.

Ibrahim JG, Chen M-H. Prior distributions and Bayesian computation for proportional hazards models. Sankhya: The Indian Journal of Statistics 1998; 60(B):48-64.

Ibrahim JG, Ryan LM, Chen M-H. Using historical controls to adjust for covariates in trend tests for binary data. J Am Stat Assoc 1998; 93(444): 1282-1293.

Jiroutek MR, Chen MH, Slemenda C, Johnston C, Longscope C. Changes in reproductive hormones and SHBG in a group of postmenopausal women measured over 10 years. Menopause: The Journal of the North American Menopause Society 1998; 5(2):90-94.

Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH, Mabry M. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology group Study. Cancer 1998; 83:1102-8.

Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, Manola J, Gelman R, Etemad-Moghadam B, Desjardins E, Wyatt R, Gerard NP, Marcon L, Margolin D, Fanton J, Axthelm MK, Letvin NL, Sodroski J. The envelope glycoprotein ectodomains determine the efficiency of CD4+ lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med 1998; 188(6): 1159-1171.

Kay NE, Leong T, Bone N, Kyle RA, Greipp PR, Van Ness B, Oken MM. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematology 1998; 100:459-463.

Keller SM, Ryan LM, Coia LR, Dang P, Vaught DJ, Diggs C, Weiner LM, Benson AB. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction. Results of a Phase II study of the Eastern Cooperative Oncology Group. Cancer 1998; 83:1908-16.

Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang H-G, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1999; 9:3379-3389.

Kleinman KP, Ibrahim JG, Laird NM. A Bayesian framework for intent-to-treat analysis with missing data. Biometrics 1998; 54:265-278.

Kleinman KP, Ibrahim JG. A semiparametric Bayesian approach to the random effects model. Biometrics 1998; 54:921-938.

Kimball Dalton VM, Gelber RD, Li F, Donnelly MJ, Tarbell NJ, Sallan SE. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16(8): 2848-2853.

Kleinman KP, Ibrahim JG. A semi-parametric Bayesian approach to generalized linear mixed model. Stat Med 1998; 17:2579-2596.

Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 1998; 92(8):2725-2729.

Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. J Am Stat Assoc 1998; 93(444):1271-1281.

Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998; 17:219-238.

Lipsitz SR, Ibrahim JG. Estimating equations with incomplete categorical covariates in the Cox model. Biometrics 1998; 54: 1002-1013.

Lipsitz SR, Dear KBG, Laird NM, Molenberghs G. Tests for homogeneity of the risk difference when data are sparse. Biometrics 1998, 54:148-160.

Lipsitz SR, Parzen M, Ewell M. Inference using conditional logistic regression with missing covariates. Biometrics, Shorter Communications 1998; 54:295-303.

Lipsitz SR, Zhai LP, Molenberghs G. A semiparametric method of multiple imputation. JR Statist Soc B 1998; 60(1) 127-144.

Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE, Gilliland DG. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998; 92(12):4792-7.

Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS, Nadler LM, Gribben JG, Gilliland DG. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998; 91(12):4496-503.

Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Oncol 1998; 16(11): 3486-3492.

Mehta CR, Patel NP. Exact inference for categorical data. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Vol. 2, England, UK: John Wiley & Sons Ltd, 1998:1411-22.

Mehta CR, Patel NP. StatXact. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Vol. 4, England, UK: John Wiley & Sons Ltd, 1998:4302-4303.

Meta-analysis Group in Cancer (Ryan LM-ECOG). Efficacy of intravenous Continuous infustion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.

Meta-Analysis Group in Cancer (Ryan LM;Harrington DP-ECOG). Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.

Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma (MM), an Eastern Cooperative Oncology Group (ECOG) Study (E1A93). Am J Clin Oncol 1998; 21(6): 553-556.

Neymark N, Kiebert W, Torfs K, Davies L, Fayers P, Hillner B, Gelber R, Guyatt G, Kind P, Machin D, Nord E, Osoba D, Revicki D, Schulman K, Simpson K. Methodological and statistical issues of quality of life (QOL) and economic evaluation in cancer clinical trials: report of a workshop. European J Cancer 1998; 34(9):1317-1333.

Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16(4): 1287-1293.

Nixon AJ, Manola J, Gelman R, Bornstein B, Abner A, Hetelekidis S, Recht A, Harris JR. No long-term increase in cardiac-related mortality after breast -conserving surgery and radiation therapy using modern techniques. J Clin Oncol 1998; 16(4):1374-1379.

Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:545-550.

Padungtod C, Lasely BL, Christiani DC, Ryan LM, Xu X. Reproductive hormone profile among pesticide factory workers. J Occup Environ Med 1998; 40(12):1038-47.

Pagani Q, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C.-M, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn HJ. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34:632-640, 1998.

Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH, for the Eastern Cooperative Oncology Group. Biologic heterogeneity in Philadelphia chromosome positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group. Leukemia. 1998; 12(12):1881-5.

Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 1998; 83:1529-1539.

Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998; 83:748-752.

Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998; 92(3):737-44.

Ryan LM, Soper KA. Preclinical treatment evaluation. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Vol. 4, England, UK: John Wiley & Sons, Ltd, 1998: 3467-3471.

Schmitz JE, Forman MA, Lifton MA, Concepcion O, Reimann KA, Crumpacker CS, Daley JF, Gelman RS, Letvin NL. Expression of the CD8-heterodimer on CD8⁺ T Lymphocytes in peripheral blood lymphocytes of human immunodeficiency virus^- and human immunodeficiency virus⁺ individuals. Blood 1998; 92(1): 198-206.

Shapiro CL, Harrigan-Hardenbergh P, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16(11):3493-3501.

Smith TJ, Ryan LM, Douglass HO, Haller DG, Dayal Y, Kirkwood J, Tormey DC, Schutt AJ, Hinson J, Sischy B. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the espophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42(2): 269-276.

Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L; Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J. CD6+ T cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation. 1998; 21(12):1177-81.

Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hod FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KT, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci 1998; 95:13141-13146.

Stoler JM, Huntington KS, Peterson CM, Peterson KP, Daniel P, Aboagye KK, Lieberman E, Ryan L, Holmes LB. The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediat 1998; 133(3):346-352.

Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16(8):2583-2590.

Talcott JA, Rieker P, Clark JA, Propert KJ, Weels KC. Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16(1): 275-283.

Troxel AB, Harrington DP, Lipsitz SR. Analysis of longitudinal data with non-ignorable non-monotone missing values. Applied Statistics 1998; 47(3):425-438.

Troxel AB, Lipsitz SR, Harrington DP. Marginal models for the analysis of longitudinal measurements with nonignorable non-monotone missing data. Biometrika 1998; 85(3):661-672.

Wadler S, Atkins M, Karp D, Neuberg D, Haynes H, Dutcher JP. Clinical trials of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon -2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. The Cancer Journal from Scientific American 1998; 4(4):261-268.

Wallace BC, Zelen M, Zani Pacheco CL. Milk leakage in nonlactating women: a randomized clinical trial evaluating a polyvinyl chloride device versus disposable breast pads. J Women's Health 1998:7(8):1283-1288.

Weller EA, Ryan LM. Testing for trend with count data. Biometrics. 1998; 54:762-773.

Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998; 16:191-195.

Xu X, Cho SI, Sammel M, You L, Cui S, Huang Y, Ma G, Padungtod C, Pothier L, Niu T, Christiani D, Smith T, Ryan L, Wang L. Association of petrochemical exposure with spontaneous abortion. J Occup Environ Med 1998; 55(1):31-36.

Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W-M, Anderson I, Shipp MA. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-hodgkin's lymphoma. Blood 1998; 91(11):4282-4291.

Zelen M. Inference. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Vol. 3, England, UK: John Wiley & Sons, Ltd, 1998:2034-46.

Zelen M. Comment on Clinician Preferences by Edward L Korn and Sheldon Baumrind (Stat Sci 1998; 13:209-235). Stat Sci 1998; 13:228.